MedTrace Logo

Chiglitazar Added to Metformin for Type 2 Diabetes

NCT04807348 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 533

Last updated 2024-07-15

No results posted yet for this study

Summary

The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type 2 diabetes Inadequately controlled with metformin Monotherapy.

Conditions

Interventions

DRUG

Chiglitazar 32mg

Administrated once daily

DRUG

Chiglitazar 48mg

Administrated once daily

DRUG

Placebo

Placebo of Chiglitazar

DRUG

Metformin Hydrochloride

most tolerable dose

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Principal Investigators

  • Linong Ji, Prof. · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2023-02-10
Completion
2023-02-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04807348 on ClinicalTrials.gov